Anandamide

Anandamide is a lipid of Fatty Acyls (FA) class. Anandamide is associated with abnormalities such as Dehydration. The involved functions are known as Process, Phenomenon, Phosphorylation, Catabolic Process and Gene Expression. Anandamide often locates in Nuchal region, Microglial and Hepatic. The associated genes with Anandamide are SGPL1 gene, SPTLC1 gene, RPSA gene, KDSR gene and SMPD1 gene. The related lipids are Sphingolipids, Lipopolysaccharides, Lysophospholipids, LYSO-PC and lysophosphatidylethanolamine.

Cross Reference

Introduction

To understand associated biological information of Anandamide, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Anandamide?

Anandamide is suspected in Dehydration and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Anandamide

MeSH term MeSH ID Detail
Stomach Ulcer D013276 75 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Breast Neoplasms D001943 24 associated lipids
Neoplasms D009369 13 associated lipids
Pain D010146 64 associated lipids
Inflammation D007249 119 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Diabetic Retinopathy D003930 39 associated lipids
Fatty Liver D005234 48 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Hypotension D007022 41 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Melanoma D008545 69 associated lipids
Per page 10 20 50 100 | Total 105

PubChem Associated disorders and diseases

What pathways are associated with Anandamide

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Anandamide?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Anandamide?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Anandamide?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Anandamide?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Anandamide?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Anandamide

Download all related citations
Per page 10 20 50 100 | Total 2222
Authors Title Published Journal PubMed Link
Berger C et al. Massive accumulation of N-acylethanolamines after stroke. Cell signalling in acute cerebral ischemia? 2004 J. Neurochem. pmid:15009671
Price TJ et al. Modulation of trigeminal sensory neuron activity by the dual cannabinoid-vanilloid agonists anandamide, N-arachidonoyl-dopamine and arachidonyl-2-chloroethylamide. 2004 Br. J. Pharmacol. pmid:15006899
Sun YX et al. Biosynthesis of anandamide and N-palmitoylethanolamine by sequential actions of phospholipase A2 and lysophospholipase D. 2004 Biochem. J. pmid:14998370
Steffens M et al. Cannabinoid CB1 receptor-mediated modulation of evoked dopamine release and of adenylyl cyclase activity in the human neocortex. 2004 Br. J. Pharmacol. pmid:14993102
Costanzi M et al. Effects of anandamide and morphine combinations on memory consolidation in cd1 mice: involvement of dopaminergic mechanisms. 2004 Neurobiol Learn Mem pmid:14990234
Fernández-Solari J et al. Alcohol inhibits luteinizing hormone-releasing hormone release by activating the endocannabinoid system. 2004 Proc. Natl. Acad. Sci. U.S.A. pmid:14981261
Basta PV et al. Preparation of monoclonal antibodies reactive to the endogenous small molecule, anandamide. 2004 J. Immunol. Methods pmid:14980433
Guo J and Ikeda SR Endocannabinoids modulate N-type calcium channels and G-protein-coupled inwardly rectifying potassium channels via CB1 cannabinoid receptors heterologously expressed in mammalian neurons. 2004 Mol. Pharmacol. pmid:14978245
Ligresti A et al. Further evidence for the existence of a specific process for the membrane transport of anandamide. 2004 Biochem. J. pmid:14969584
Lin GC et al. Gap junctional communication modulates agonist-induced calcium oscillations in transfected HeLa cells. 2004 J. Cell. Sci. pmid:14762115
Matias I et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology and metabolism. 2004 J. Pharmacol. Exp. Ther. pmid:14757851
Moezi L et al. Potentiation of anandamide effects in mesenteric beds isolated from bile duct-ligated rats: role of nitric oxide. 2004 Eur. J. Pharmacol. pmid:14751408
Dennedy MC et al. Cannabinoids and the human uterus during pregnancy. 2004 Am. J. Obstet. Gynecol. pmid:14749627
Murillo-Rodriguez E et al. Anandamide enhances extracellular levels of adenosine and induces sleep: an in vivo microdialysis study. 2003 Sleep pmid:14746372
de Lago E et al. In vivo pharmacological actions of two novel inhibitors of anandamide cellular uptake. 2004 Eur. J. Pharmacol. pmid:14744610
Weber A et al. Formation of prostamides from anandamide in FAAH knockout mice analyzed by HPLC with tandem mass spectrometry. 2004 J. Lipid Res. pmid:14729864
Maccarrone M Inhibition of anandamide hydrolysis: cells also know how to do it. 2004 Trends Mol Med pmid:14720580
Akerman S et al. Anandamide is able to inhibit trigeminal neurons using an in vivo model of trigeminovascular-mediated nociception. 2004 J. Pharmacol. Exp. Ther. pmid:14718591
Ruiz-Llorente L et al. Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study. 2004 Br. J. Pharmacol. pmid:14718261
Lees G and Dougalis A Differential effects of the sleep-inducing lipid oleamide and cannabinoids on the induction of long-term potentiation in the CA1 neurons of the rat hippocampus in vitro. 2004 Brain Res. pmid:14715144
Devane WA et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. 1992 Science pmid:1470919
Piomelli D THC: moderation during implantation. 2004 Nat. Med. pmid:14702623
Kasai HF et al. Analyses of anandamide and endocannabinoid-like compounds using collision-induced dissociation in fast atom bombardment ionization-mass spectrometry and gas chromatography/chemical ionization-mass spectrometry. 2003 Anal Sci pmid:14696920
Wenger T et al. The endogenous cannabinoid, anandamide, activates the hypothalamo-pituitary-adrenal axis in CB1 cannabinoid receptor knockout mice. 2003 Neuroendocrinology pmid:14688442
Motobe T et al. Endogenous cannabinoids are candidates for lipid mediators of bone cement implantation syndrome. 2004 Shock pmid:14676677
Arizzi MN et al. Behavioral effects of inhibition of cannabinoid metabolism: The amidase inhibitor AM374 enhances the suppression of lever pressing produced by exogenously administered anandamide. 2004 Life Sci. pmid:14672756
Nilsson O et al. Cannabinoid CB1 receptor activation does not prevent the toxicity of glutamate towards embryonic chick telencephalon primary cultures. 2003 Comp. Biochem. Physiol. C Toxicol. Pharmacol. pmid:14659458
Wang H et al. Differential G protein-coupled cannabinoid receptor signaling by anandamide directs blastocyst activation for implantation. 2003 Proc. Natl. Acad. Sci. U.S.A. pmid:14645706
Zoratti C et al. Anandamide initiates Ca(2+) signaling via CB2 receptor linked to phospholipase C in calf pulmonary endothelial cells. 2003 Br. J. Pharmacol. pmid:14645143
Jones S and Howl J Cannabinoid receptor systems: therapeutic targets for tumour intervention. 2003 Expert Opin. Ther. Targets pmid:14640910
Farquhar-Smith WP and Rice AS A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. 2003 Anesthesiology pmid:14639155
Kollarik M and Undem BJ Activation of bronchopulmonary vagal afferent nerves with bradykinin, acid and vanilloid receptor agonists in wild-type and TRPV1-/- mice. 2004 J. Physiol. (Lond.) pmid:14634201
Okamoto Y et al. Molecular characterization of a phospholipase D generating anandamide and its congeners. 2004 J. Biol. Chem. pmid:14634025
Sparling PB et al. Exercise activates the endocannabinoid system. 2003 Neuroreport pmid:14625449
Seagard JL et al. Anandamide content and interaction of endocannabinoid/GABA modulatory effects in the NTS on baroreflex-evoked sympathoinhibition. 2004 Am. J. Physiol. Heart Circ. Physiol. pmid:14615281
McAllister SD et al. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. 2003 J. Med. Chem. pmid:14613317
Gaetani S et al. Anandamide hydrolysis: a new target for anti-anxiety drugs? 2003 Trends Mol Med pmid:14604824
Egashira N et al. Anandamide inhibits the DOI-induced head-twitch response in mice. 2004 Psychopharmacology (Berl.) pmid:14586538
Biswas KK et al. Membrane cholesterol but not putative receptors mediates anandamide-induced hepatocyte apoptosis. 2003 Hepatology pmid:14578855
Johnson RP et al. System-specific O2 sensitivity of the tandem pore domain K+ channel TASK-1. 2004 Am. J. Physiol., Cell Physiol. pmid:14576090
Chen N et al. Inhibition by arachidonic acid and other fatty acids of dopamine uptake at the human dopamine transporter. 2003 Eur. J. Pharmacol. pmid:14575792
Han B et al. Semiplenamides A-G, fatty acid amides from a Papua New Guinea collection of the marine cyanobacterium Lyngbya semiplena. 2003 J. Nat. Prod. pmid:14575438
Steffens M et al. Quantitative measurement of depolarization-induced anandamide release in human and rat neocortex. 2003 Naunyn Schmiedebergs Arch. Pharmacol. pmid:14566450
Maccarrone M et al. Endocannabinoid degradation, endotoxic shock and inflammation. 2002 Curr Drug Targets Inflamm Allergy pmid:14561206
Gurney AM et al. Two-pore domain K channel, TASK-1, in pulmonary artery smooth muscle cells. 2003 Circ. Res. pmid:14551239
Marsicano G et al. CB1 cannabinoid receptors and on-demand defense against excitotoxicity. 2003 Science pmid:14526074
Mechoulam R and Lichtman AH Neuroscience. Stout guards of the central nervous system. 2003 Science pmid:14526067
Vandevoorde S et al. Esters, retroesters, and a retroamide of palmitic acid: pool for the first selective inhibitors of N-palmitoylethanolamine-selective acid amidase. 2003 J. Med. Chem. pmid:14521402
Ross RA Anandamide and vanilloid TRPV1 receptors. 2003 Br. J. Pharmacol. pmid:14517174
Fowler CJ et al. Inhibition of fatty acid amidohydrolase, the enzyme responsible for the metabolism of the endocannabinoid anandamide, by analogues of arachidonoyl-serotonin. 2003 J Enzyme Inhib Med Chem pmid:14506913